Myomo, Inc., (“Myomo” or the “Company”), a commercial stage medical robotics company, announced today that it is hosting a live, interactive webinar of the Company’s $15 million Reg A+ IPO investment opportunity, followed by a Q&A with Myomo CEO, Paul R. Gudonis. The investor webinar will take place on Tuesday, March 28th at 2:00pm EDT.
Myomo's investor webinar will include discussion on the Company's plans for growth as well as its non-invasive technology, exclusively licensed from Massachusetts Institute of Technology, which restores a patient’s ability to use their partially paralyzed or weakened arms and hands again so they can return to work, live independently and reduce their cost of care. Due to the large number of strokes, spinal cord injuries, and other neurological conditions that occur each year, the MyoPro® has the capability to help millions of individuals worldwide.
“We are very excited to share our vision of restoring upper limb to the large number of individuals impacted by paralysis with a broad set of individual investors that now have the opportunity to invest in our Company, alongside accredited investors and institutions, at our initial offering price,” said Mr. Gudonis. “While a traditional public offering is generally reserved for large institutions and the Wall Street elite to invest at this stage, we are taking advantage of new SEC regulations to level the playing field for all investors to participate concurrently in our IPO.”
The Company seeks to raise up to $15 million in its IPO under Regulation A+ and then, in succession and subject to NYSE requirements, be listed on the NYSE MKT as “MYO.” TriPoint Global Equities, LLC, working with its online division BANQ® (www.banq.co), will act as the lead managing selling agent and bookrunner for the offering. Myomo intends to use the proceeds from the offering to fund sales and marketing, product development, repayment of debt, and for working capital and other general corporate purposes. To learn more about the IPO or to invest visit www.banq.co/listings/myomo
To register for the webinar, please visit http://events.shindig.com/event/tripointmyomo.
About Myomo, Inc.
Myomo, Inc. is a commercial stage medical robotics Company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Based on patented technology developed at MIT and the Company, Myomo develops and markets the MyoPro® product line of lightweight, non-invasive, powered arm braces to restore function in the paralyzed or weakened arms and hands of individuals that have suffered a stroke, spinal cord or nerve injury such as brachial plexus injury, or other neuromuscular disability such as amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). It is provided through clinical relationships with VA medical centers, leading rehabilitation hospitals, and Orthotics and Prosthetics (“O&P”) practices. Several hundred have been successfully used by patients. It is the only device that, sensing a patient’s own neurological signals through non-invasive sensors on the arm, can restore their ability to use their arms and hands so that they can return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. For more information, please visit www.myomo.com.
Myomo Inc.’s offering statement for its initial public offering under Regulation A has been qualified by the Securities and Exchange Commission. The securities offered by Myomo Inc. are highly speculative. Investing in shares of Myomo Inc. involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. To obtain a copy of the Offering Circular, go to Myomo Form 1-A at https://goo.gl/z7npq1.
This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the Company, expressed by such language as “expected,” “anticipated,” “projected” and “forecasted.” Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the Company. Forward-looking statements may be based on management assumptions that prove to be wrong. The Company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the Company incurring operating losses and experiencing unexpected material adverse events.